Amgen Cites Strength From Being Both Innovator And Developer In Biosimilars Space
This article was originally published in The Pink Sheet Daily
Executive Summary
Struggling to both contain costs and put extra muscle behind its new products and late-stage candidates, Amgen also finds itself torn between roles as an innovator and a firm pursuing biosimilar approvals of other companies’ drugs.